The Journal of Practical Medicine >

2023 , Vol. 39 >Issue 23: 3043 - 3050

DOI: https://doi.org/10.3969/j.issn.1006-5725.2023.23.004

Basic Research

Impact of LncRNA DSCAM⁃AS1 on the malignant biological behaviors of thyroid cancer cells by regulating the miR⁃150⁃5p/BRAF axis

  • Yun PENG ,
  • Meiling WEN ,
  • Yunxia LV ,
  • Wanzhi CHEN ,
  • Chun HE ,
  • Jianping YU ,
  • Zhenluo. DING
Expand
  • *.Department of Thyroid Surgery，People's Hospital of Ganzhou，Ganzhou 341000，China

Received date: 2023-06-30

  Online published: 2024-01-08

Fold

Abstract

Objective To investigate the impact of lncRNA DSCAM-AS1 on the malignant biological behaviors of thyroid cancer （TC） cells by regulating the miR-150-5p/BRAF axis. Methods The expression of DSCAM-AS1 in TC cells was detected by qRT-PCR，and the best intervention cell line was screened.； the relationship between DSCAM-AS1， BRAF and miR-150-5p targeting regulation was verified by FISH， pull down and double Luciferase reporter gene experiment； The proliferation，migration and invasion of SW579 cells were detected； Western blot was applied to detect the expression of BRAF， E-Cadherin， and vimentin proteins； the tumor formation experiment in mice was applied to verify the effect of DSCAM-AS1 on TC tumor growth. Results DSCAM-AS1 was highly expressed in TC tissue and cells （P < 0.05）； There is a targeted regulation relationship between DSCAM-AS1，BRAF and miR-150-5p； inhibition of DSCAM-AS1 expression or overexpression of miR-150-5p obviously inhibited the proliferation， migration， invasion， and EMT of SW579 cells （P < 0.05）； Inhibition of miR-150-5p expression or overexpression of BRAF reversed the inhibitory effect of inhibition of DSCAM-AS1 expression or overexpression of miR-150-5p on the malignant behavior of SW579 cells （P < 0.05）； in vivo experiments showed that inhibiting the expression of DSCAM-AS1 obviously inhibited the growth of transplanted tumors in mice （P < 0.05）. Conclusion DSCAM-AS1 is up-regulated in TC cells， inhibiting the expression of LncRNA DSCAM-AS1 can inhibit the malignant progression of TC by regulating the miR-150-5p/BRAF signaling axis.

Key words： lncRNA DSCAM-AS1; miR-150-5p/BRAF axis; thyroid cancer; proliferation; migration; invasion

Cite this article

Yun PENG , Meiling WEN , Yunxia LV , Wanzhi CHEN , Chun HE , Jianping YU , Zhenluo. DING . Impact of LncRNA DSCAM⁃AS1 on the malignant biological behaviors of thyroid cancer cells by regulating the miR⁃150⁃5p/BRAF axis[J]. The Journal of Practical Medicine, 2023 , 39(23) : 3043 -3050 . DOI: 10.3969/j.issn.1006-5725.2023.23.004

References

1 ZHOU Y， LIU S， LUO Y，et al. IncRNA MAPKAPK5-AS1 promotes proliferation and migration of thyroid cancer cell lines by targeting miR-519e-5p/YWHAH［J］. Eur J Histochem，2020，64（4）：3177-3185.
2 HU J， YUAN I J， MIRSHAHIDI S，et al. Thyroid Carcinoma： Phenotypic Features，Underlying Biology and Potential Relevance for Targeting Therapy［J］. Int J Mol Sci，2021，22（4）：1950-1974.
3 WANG S， LUO J， ZHONG Z，et al. Treatment and prognosis for patients with differentiated thyroid carcinoma bone metastases［J］. Transl Cancer Res，2020，9（1）：972-982.
4 TAN Y T， LIN J F， Li T，et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer［J］. Cancer Commun （Lond），2021，41（2）：109-120.
5 WANG Z， LI S， ZHANG G. LncRNA DSCAM-AS1 Negatively Interacts with miR-124 to Promote Hepatocellular Carcinoma Proliferation［J］. Crit Rev Eukaryot Gene Expr，2022，32（3）：1-8.
6 LI L， CHEN P， HUANG B，et al. lncRNA DSCAM-AS1 facilitates the progression of endometrial cancer via miR-136-5p［J］. Oncol Lett，2021，22（6）：825-833.
7 YU C L， XU N W， JIANG W，et al. LncRNA DSCAM-AS1 promoted cell proliferation and invasion in osteosarcoma by sponging miR-101［J］. Eur Rev Med Pharmacol Sci， 2020，24（14）：7709-7717.
8 GUO K， QIAN K， SHI Y，et al. LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p［J］. Cell Death Dis， 2021，12（12）：1097-1108.
9 WEI X， WANG X， XIONG J，et al. Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma. Biomed Res Int［J］. 2022，2022（1）：1-13.
10 GUO F， FU Q， WANG Y，et al. Long non-coding RNA NR2F1-AS1 promoted proliferation and migration yet suppressed apoptosis of thyroid cancer cells through regulating miRNA-338-3p/CCND1 axis［J］. J Cell Mol Med，2019，23（9）：5907-5919.
11 余江涛，王世杰，张高飞，等. 血清甲状腺球蛋白、促甲状腺激素联合检测对行甲状腺全切术后未接受清甲治疗的分化型甲状腺癌患者复发的预测价值［J］. 实用医学杂志，2023，39（9）：1159-1163.
12 SHI L， CONG Y Z， WANG Z J. LncRNA NORAD promotes thyroid carcinoma progression by targeting miR-451［J］. Eur Rev Med Pharmacol Sci， 2021，25（20）：6187-6195.
13 LIU H， DENG H， ZHAO Y，et al. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling［J］. J Exp Clin Cancer Res， 2018，37（1）：279-290.
14 LU C， XIE T， GUO X，et al. LncRNA DSCAM-AS1 Promotes Colon Cancer Cells Proliferation and Migration via Regulating the miR-204/SOX4 Axis［J］. Cancer Manag Res， 2020，12（1）：4347-4356.
15 SHETTY A， VENKKANESH T， KABBEKOUDU S P，et al. LncRNA-miRNA-mRNA regulatory axes in endometrial cancer： a comprehensive overview［J］. Arch Gynecol Obstet， 2022，306（5）：1431-1447.
16 CHEN X， XU X， PAN B，et al. miR-150-5p suppresses tumor progression by targeting VEGFA in colorectal cancer［J］. Aging （Albany NY）， 2018，10（11）：3421-3437.
17 DAI F Q， LI C R， FAN X Q，et al. miR-150-5p Inhibits Non-Small-Cell Lung Cancer Metastasis and Recurrence by Targeting HMGA2 and β-Catenin Signaling［J］. Mol Ther Nucleic Acids，2019，16（1）：675-685.
18 李文强，刘慧颖，任卫东. 干扰Hsa_circ_0023642调控miR-653对甲状腺癌细胞生物行为的影响［J］. 实用医学杂志， 2021，37（21）：2727-2732.
19 李秀君，刘宝利，朱翠敏. lncRNA TUG1通过miR-524-5p/BRAF轴调节甲状腺乳头状癌TPC-1细胞的增殖、凋亡和EMT进程［J］. 中国肿瘤生物治疗杂志， 2022，29（5）：434-441.
20 MAZIERES J， CROPET C， MONTANE L，et al. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations［J］. Ann Oncol， 2020，31（2）：289-294.
21 MORRIS V K， BEKAII-SABB T. Improvements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer［J］. Clin Cancer Res， 2020，26（17）：4435-4441.
22 CHUNG J H. BRAF and TERT promoter mutations： clinical application in thyroid cancer［J］. Endocr J， 2020，67（6）：577-584.
23 SUBBIASH V， BAIK C， KIRKWOOD J M. Clinical Development of BRAF plus MEK Inhibitor Combinations［J］. Trends Cancer，2020，6（9）：797-810.
24 CUCCURULLO V， STASIO G D， CASCINI G L. PET/CT in thyroid cancer - the importance of BRAF mutations［J］. Nucl Med Rev Cent East Eur， 2020，23（2）：97-102.
Options
Outlines

/

〈 〉